Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Given Consensus Recommendation of "Hold" by Brokerages

Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Get Free Report) have been given a consensus recommendation of "Hold" by the twelve analysts that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and four have issued a buy rating on the company. The average 12 month price objective among analysts that have covered the stock in the last year is $6.64.

A number of research analysts have recently issued reports on MRVI shares. Stifel Nicolaus set a $5.00 target price on shares of Maravai LifeSciences in a research note on Friday, March 21st. UBS Group dropped their target price on shares of Maravai LifeSciences from $8.00 to $2.50 and set a "neutral" rating for the company in a research report on Friday, March 21st. Craig Hallum reduced their price objective on shares of Maravai LifeSciences from $12.00 to $10.00 and set a "buy" rating on the stock in a research note on Tuesday. Bank of America decreased their target price on Maravai LifeSciences from $9.00 to $8.00 and set a "buy" rating for the company in a research note on Monday, March 3rd. Finally, Morgan Stanley dropped their price target on Maravai LifeSciences from $7.00 to $5.00 and set an "equal weight" rating on the stock in a research note on Tuesday, March 25th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Performa Ltd US LLC increased its stake in Maravai LifeSciences by 614.3% during the 4th quarter. Performa Ltd US LLC now owns 5,000 shares of the company's stock worth $27,000 after acquiring an additional 4,300 shares during the period. FNY Investment Advisers LLC boosted its position in Maravai LifeSciences by 600.0% in the fourth quarter. FNY Investment Advisers LLC now owns 7,000 shares of the company's stock valued at $38,000 after buying an additional 6,000 shares in the last quarter. Farther Finance Advisors LLC grew its position in Maravai LifeSciences by 3,541.4% during the 4th quarter. Farther Finance Advisors LLC now owns 10,196 shares of the company's stock worth $56,000 after acquiring an additional 9,916 shares during the last quarter. Cibc World Markets Corp bought a new position in Maravai LifeSciences in the fourth quarter valued at about $56,000. Finally, Atria Investments Inc acquired a new stake in shares of Maravai LifeSciences during the fourth quarter valued at about $58,000. 50.25% of the stock is owned by institutional investors and hedge funds.

Maravai LifeSciences Price Performance

Shares of Maravai LifeSciences stock opened at $1.96 on Friday. Maravai LifeSciences has a 52 week low of $1.67 and a 52 week high of $11.56. The stock has a market cap of $498.50 million, a PE ratio of -1.20 and a beta of 0.19. The company's 50-day moving average price is $2.11 and its two-hundred day moving average price is $4.09. The company has a current ratio of 10.74, a quick ratio of 9.94 and a debt-to-equity ratio of 0.89.

Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) last announced its earnings results on Monday, May 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.01). The firm had revenue of $46.85 million for the quarter, compared to analyst estimates of $44.01 million. Maravai LifeSciences had a negative net margin of 81.13% and a negative return on equity of 6.61%. Maravai LifeSciences's quarterly revenue was down 26.9% on a year-over-year basis. As a group, sell-side analysts anticipate that Maravai LifeSciences will post -0.24 EPS for the current fiscal year.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.